Issue Contents:  Mar 9, 2010

• Genmab Shares Dive Sharply on Zalutumumab Phase III Miss
• Infection Deaths Halt Biogen, Roche Arthritis Drug Program
• Complex Interactions Simpler at Level of Individual Protein
• Chelsea Adds $18M, Amended Droxidopa Study Nears Finish
• U.S. Patent Disclosures
• Stock Movers
• Other News To Note
• Clinic Roundup

      The above issue is also available as one PDF File